2 results
Approved WMOCompleted
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
Approved WMORecruiting
The main objective of this trial will be to get a better insight in the influence of age and age-related changes by internal and external factors on vaccine-induced immune responses and gain knowledge on the trajectory of immune decline in older…